UTv Videos

Experts discuss the implications of the FDA’s potential pathway to expand testosterone replacement therapy labeling for low libido in men with idiopathic hypogonadism.

Kyle M. Rose, MD, discusses key considerations for optimizing the timing and sequencing of inguinal and pelvic lymph node dissection.

Akanksha Mehta, MD, MS, discusses updated recommendations from the 2026 AUA Vasectomy Guideline on vas isolation and occlusion techniques.

Fred Saad, MD, FRCS, discusses findings from a post hoc analysis of the phase 3 ARANOTE trial.

Medtronic's Touch Surgery enterprise platform, integrated with the Hugo robotic system, offers AI-driven case segmentation, real-time anatomic overlay, and two-way telementoring capabilities that James R. Porter, MD, describes as the most robust digital offering currently available on a robotic surgery platform.

Meri-Margaret Deoudes discusses findings from BCAN's New Faces of Bladder Cancer Report.

Daniel J. George, MD, highlights patient-reported outcomes and tolerability findings from the phase 3 CAPItello-281 trial, evaluating the addition of capivasertib to abiraterone in patients with PTEN-deficient de novo mHSPC.

Minas P. Economides, MD, discusses the evolving role of biomarkers such as KIM-1 in refining risk stratification and highlighted emerging innovations that may reshape how kidney cancer is both imaged and therapeutically targeted.

In this video, Jennifer Miles-Thomas, MD, recaps a SUFU 2026 discussion on leveraging surgeon–APP collaborations in urology.

Akanksha Mehta, MD, MS, highlights key recommendations on pre-vasectomy counseling from the American Urological Association’s 2026 Vasectomy Guideline.

Stacy Loeb, MD, MSc, discusses emerging data on microplastics and prostate cancer and highlights practical steps to reduce plastic exposure.

Michelle Van Kuiken, MD, highlights a SWIU 2026 panel discussion on setting boundaries.

Jonathan F. Anker, MD, PhD, discusses findings from the phase 2 HCRN GU 20-444 trial, evaluating a response-adapted, bladder-sparing approach using pembrolizumab monotherapy in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin chemotherapy.

High-powered holmium and thulium laser platforms are expanding ureteroscopic options for complex patients, including those on anticoagulation, while emerging technologies such as Break Wave lithotripsy and ultrasonic propulsion may offer future office-based alternatives to traditional surgical stone management.

Daniel George, MD, discusses key efficacy findings from the phase 3 CAPItello-281 trial evaluating capivasertib plus abiraterone vs placebo plus abiraterone in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.

Alexandra Drakaki, MD, discusses guidance from a modified Delphi panel on managing peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma receiving enfortumab vedotin.

David Morris, MD, FACS, discusses expert panel recommendations on intravesical drug-releasing systems in bladder cancer, highlighting early drug release dynamics, tolerability, and optimizing patient comfort.

Giulia Almiron da R. Soares discusses survey findings examining the factors influencing women’s decisions to pursue careers in urology.

Christopher M. Pieczonka, MD, discusses practical strategies to optimize tolerability and minimize early discontinuation with indwelling intravesical drug-releasing systems for bladder cancer.

Hugo's 7-degree-of-freedom instrumentation, power-based electrosurgical architecture, and visual haptic feedback support precise reconstructive performance, while the platform's strong IDE trial outcomes are attributed to a proficiency-based progression training model that assesses both surgeons and operative teams before independent practice.

Matthias Saar, MD, discusses findings from the phase 2 INDUCTA study, evaluating the use of inductive hormonal therapy to achieve operability in patients with T4 prostate cancer.

Despite promising candidates across tumor, immune, and systemic marker categories, no biomarker yet reliably predicts BCG response or identifies which NMIBC patients would benefit from adding checkpoint inhibitor therapy—a gap that limits informed shared decision-making and broader adoption of IO-BCG combinations despite positive trial data.

Meri-Margaret Deoudes discusses findings from the Bladder Cancer Advocacy Network’s "New Faces of Bladder Cancer" survey.

Daniel Shapiro, MD, FACS, discusses how emerging biomarker strategies and evolving combination therapies are reshaping risk stratification and treatment decision-making in kidney cancer.

Anjali Kapur, MD, discusses a post-market analysis of the safety of the eCoin implantable tibial nerve stimulator for patients with urge urinary incontinence.

Dalia Kaakour, MD, MPH, highlights key findings from a retrospective review of cardiovascular system toxicities in patients initiating novel hormonal therapies for advanced prostate cancer.

Bogdana Schmidt, MD, MPH, identified several subgroups most likely to harbor occult systemic disease and therefore potentially benefit from adding immunotherapy to BCG:

Matthew D. Galsky, MD, discusses the mechanism of action for FX-909, a first-in-class agent targeting PPARγ in advanced urothelial carcinoma.